CN115279398B - 治疗液态癌症的组合物和方法 - Google Patents

治疗液态癌症的组合物和方法 Download PDF

Info

Publication number
CN115279398B
CN115279398B CN202080082229.8A CN202080082229A CN115279398B CN 115279398 B CN115279398 B CN 115279398B CN 202080082229 A CN202080082229 A CN 202080082229A CN 115279398 B CN115279398 B CN 115279398B
Authority
CN
China
Prior art keywords
protein
cell
amino acid
domain
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080082229.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN115279398A (zh
Inventor
J·M·格尔克
A·D·爱德华兹
R·默里
W·卡西姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Bim Medical Co ltd
Original Assignee
UCL Business Ltd
Bim Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd, Bim Medical Co ltd filed Critical UCL Business Ltd
Priority to CN202510808723.2A priority Critical patent/CN120905310A/zh
Publication of CN115279398A publication Critical patent/CN115279398A/zh
Application granted granted Critical
Publication of CN115279398B publication Critical patent/CN115279398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080082229.8A 2019-09-27 2020-09-25 治疗液态癌症的组合物和方法 Active CN115279398B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510808723.2A CN120905310A (zh) 2019-09-27 2020-09-25 治疗液态癌症的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907254P 2019-09-27 2019-09-27
US62/907,254 2019-09-27
PCT/US2020/052822 WO2021062227A2 (en) 2019-09-27 2020-09-25 Compositions and methods for treatment of liquid cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510808723.2A Division CN120905310A (zh) 2019-09-27 2020-09-25 治疗液态癌症的组合物和方法

Publications (2)

Publication Number Publication Date
CN115279398A CN115279398A (zh) 2022-11-01
CN115279398B true CN115279398B (zh) 2025-07-04

Family

ID=75166843

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080082229.8A Active CN115279398B (zh) 2019-09-27 2020-09-25 治疗液态癌症的组合物和方法
CN202510808723.2A Pending CN120905310A (zh) 2019-09-27 2020-09-25 治疗液态癌症的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510808723.2A Pending CN120905310A (zh) 2019-09-27 2020-09-25 治疗液态癌症的组合物和方法

Country Status (8)

Country Link
US (1) US12594301B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034138A4 (cg-RX-API-DMAC7.html)
JP (2) JP7615134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220090512A (cg-RX-API-DMAC7.html)
CN (2) CN115279398B (cg-RX-API-DMAC7.html)
AU (1) AU2020355222A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155667A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062227A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
EP4211245A1 (en) * 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
WO2022240858A1 (en) 2021-05-10 2022-11-17 Mammoth Biosciences, Inc. Effector proteins and methods of use
US20230279352A1 (en) * 2021-08-24 2023-09-07 Astrazeneca Ab Methods for generating primary immune cells
WO2023034475A1 (en) * 2021-09-01 2023-03-09 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
CA3242360A1 (en) * 2021-12-10 2023-06-15 Beam Therapeutics Inc. Modified immune cells and methods of using the same
WO2023137457A2 (en) * 2022-01-13 2023-07-20 Spotlight Therapeutics Immune response specific guide rnas and uses thereof
WO2023141590A2 (en) 2022-01-21 2023-07-27 Mammoth Biosciences, Inc. Effector proteins and methods of use
US20260083846A1 (en) * 2022-05-19 2026-03-26 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
JP2025532585A (ja) * 2022-09-16 2025-10-01 アーセナル バイオサイエンシズ インコーポレイテッド 組み合わせ遺伝子摂動を有する免疫細胞
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
WO2024197020A2 (en) * 2023-03-21 2024-09-26 Beam Therapeutics Inc. Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof
WO2025126049A2 (en) * 2023-12-11 2025-06-19 Crispr Therapeutics Ag Multiplex gene editing
WO2026019758A2 (en) * 2024-07-16 2026-01-22 The University Of North Carolina At Chapel Hill Engineered cas9 endonucleases with enhanced editing efficiency
WO2026077659A1 (en) * 2024-09-17 2026-04-16 Institut National de la Santé et de la Recherche Médicale Enrichment of genetically modified hematopoietic stem cells through epigenome editing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075483A (zh) * 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 用于过继细胞治疗的工程改造的细胞
WO2018165631A1 (en) * 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
CN109996811A (zh) * 2016-08-03 2019-07-09 约翰·F·迪帕西奥 用于用嵌合抗原受体治疗t细胞恶性肿瘤的car-t细胞的基因编辑

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006121A1 (en) 1995-08-04 1997-02-20 Jennings, Norman, T. Compositions and method for controlling odor in organic waste material
GB9600384D0 (en) 1996-01-09 1996-03-13 Nyfotek As Dna glycosylases
JP2003514564A (ja) 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
US20040003420A1 (en) 2000-11-10 2004-01-01 Ralf Kuhn Modified recombinase
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
CA2439472A1 (en) 2001-02-27 2002-09-06 University Of Rochester Methods and compositions for modifying apolipoprotein b mrna editing
AU2002330714A1 (en) 2001-05-30 2003-01-02 Biomedical Center In silico screening for phenotype-associated expressed sequences
US7300829B2 (en) 2003-06-02 2007-11-27 Applied Materials, Inc. Low temperature process for TFT fabrication
WO2010132092A2 (en) 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
US20110104787A1 (en) 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
US20130011380A1 (en) 2009-12-18 2013-01-10 Blau Helen M Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming
WO2012004778A1 (en) 2010-07-09 2012-01-12 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
DK2699593T4 (da) 2011-04-20 2021-02-08 Univ Washington Through Its Center For Commercialization Beta-2 mikroglobulin-deficiente celler
JP6177780B2 (ja) 2011-09-28 2017-08-09 エラ、ビオテック、ソシエダッド、アノニマEra Biotech, S.A. スプリットインテインおよびその使用
CN103088008B (zh) 2011-10-31 2014-08-20 中国科学院微生物研究所 胞苷脱氨酶及其编码基因和它们的应用
BR112014020502A2 (pt) 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
EP4253409A3 (en) 2012-04-17 2023-12-06 University of Washington through its Center for Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
PT2877490T (pt) 2012-06-27 2019-02-12 Univ Princeton Inteínas clivadas, conjugados e suas utilizações
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
WO2014186686A2 (en) 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
EP3603679B1 (en) 2013-06-04 2022-08-10 President and Fellows of Harvard College Rna-guided transcriptional regulation
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ CRISPR/Cas系を用いるゲノム編集の治療用の使用
CN105517579B (zh) 2013-07-10 2019-11-15 哈佛大学校长及研究员协会 用于RNA向导的基因调节和编辑的正交Cas9蛋白
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
EP3613854A1 (en) 2014-03-05 2020-02-26 National University Corporation Kobe University Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US20170239294A1 (en) 2014-10-15 2017-08-24 Novartis Ag Compositions and methods for treating b-lymphoid malignancies
EP3212221B1 (en) 2014-10-29 2023-12-06 Massachusetts Eye & Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
JP6153180B2 (ja) 2014-11-04 2017-06-28 国立大学法人神戸大学 脱塩基反応により標的化したdna配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体
MA40921A (fr) 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
AU2015364286B2 (en) 2014-12-20 2021-11-04 Arc Bio, Llc Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using CRISPR/Cas system proteins
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
BR112017020750A2 (en) 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
EP4019975A1 (en) 2015-04-24 2022-06-29 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US20180291372A1 (en) 2015-05-14 2018-10-11 Massachusetts Institute Of Technology Self-targeting genome editing system
CN106011104B (zh) 2015-05-21 2019-09-27 清华大学 利用拆分Cas系统进行基因编辑和表达调控方法
US20160348074A1 (en) 2015-05-29 2016-12-01 Agenovir Corporation Methods and compositions for treating cells for transplant
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
EP3929287A3 (en) 2015-06-18 2022-04-13 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
JP7033453B2 (ja) 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
EP3957731A1 (en) 2015-07-15 2022-02-23 Rutgers, The State University of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
US20170020922A1 (en) 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US11242375B2 (en) 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
US11008555B2 (en) 2015-09-17 2021-05-18 The Regents Of The University Of California Variant Cas9 polypeptides comprising internal insertions
CA2999070A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US11866727B2 (en) 2015-11-06 2024-01-09 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1A
WO2017093804A2 (en) 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
WO2017132580A2 (en) 2016-01-29 2017-08-03 The Trustees Of Princeton University Split inteins with exceptional splicing activity
MX2018010484A (es) 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3020993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
SG10202109385QA (en) 2016-07-05 2021-10-28 Univ Johns Hopkins Crispr/cas9-based compositions and methods for treating retinal degenerations
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
US11180778B2 (en) 2016-11-11 2021-11-23 The Regents Of The University Of California Variant RNA-guided polypeptides and methods of use
CN107043779B (zh) 2016-12-01 2020-05-12 中国农业科学院作物科学研究所 一种CRISPR/nCas9介导的定点碱基替换在植物中的应用
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
GB201622044D0 (en) 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
JP7383478B2 (ja) 2016-12-22 2023-11-20 インテリア セラピューティクス,インコーポレイテッド アルファ1アンチトリプシン欠乏症を治療するための組成物および方法
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR102569848B1 (ko) 2016-12-23 2023-08-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
EP3565608A4 (en) 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
AU2018208614A1 (en) * 2017-01-10 2019-07-11 The General Hospital Corporation Modified T cells and methods of their use
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018152197A1 (en) 2017-02-15 2018-08-23 Massachusetts Institute Of Technology Dna writers, molecular recorders and uses thereof
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3600357A4 (en) 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
CN106916852B (zh) 2017-04-13 2020-12-04 上海科技大学 一种碱基编辑系统及其构建和应用方法
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
PL3618842T3 (pl) 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
KR102678809B1 (ko) 2017-05-18 2024-06-26 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
WO2018218066A1 (en) 2017-05-24 2018-11-29 The Regents Of The University Of California Cmv vaccine and method of making and using the same
CA3063733A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
CA3067244A1 (en) 2017-06-12 2018-12-20 Children's Healthcare Of Atlanta, Inc. T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies
CN111328290A (zh) 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
CA3069527A1 (en) 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treatment of cancers harboring an h3k27m mutation
WO2019014665A1 (en) 2017-07-14 2019-01-17 Dana-Farber Cancer Institute, Inc. MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019040650A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
IL316453A (en) 2017-10-06 2024-12-01 Univ Oregon Health & Science RNA editing agents and methods
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3723774A4 (en) 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
AR114014A1 (es) 2017-12-22 2020-07-08 Inst Genetics & Developmental Biology Cas Sistema de edición de bases y método basado en proteína cpf1
CA3090793C (en) 2018-02-16 2024-10-08 Kite Pharma, Inc. MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE
CN112292139B (zh) * 2018-03-13 2024-03-08 明尼苏达大学董事会 使用Cas9碱基编辑器的淋巴造血改造
US20210363518A1 (en) 2018-03-19 2021-11-25 University Of Massachusetts Modified guide rnas for crispr genome editing
EP3781176A4 (en) 2018-04-09 2022-05-25 The Trustees of the University of Pennsylvania METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
WO2019210207A2 (en) 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
KR102959497B1 (ko) 2018-05-11 2026-05-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR102853088B1 (ko) 2018-05-11 2025-09-02 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CN110616189B (zh) 2018-06-20 2022-02-18 西安桑尼赛尔生物医药有限公司 通用型靶向cd19抗原嵌合受体t细胞的制备及其应用
CN108753823B (zh) 2018-06-20 2022-09-23 李广磊 利用碱基编辑技术实现基因敲除的方法及其应用
WO2020010239A1 (en) 2018-07-06 2020-01-09 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptor polypeptides and methods of using same
CN108949825A (zh) 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用
KR102894715B1 (ko) 2018-08-03 2025-12-03 빔 테라퓨틱스, 인크. 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
WO2020041751A1 (en) 2018-08-23 2020-02-27 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
CN109295186B (zh) 2018-09-30 2023-10-03 中山大学 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
EP3887521A1 (en) 2018-11-29 2021-10-06 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CA3121911A1 (en) 2018-12-06 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
AU2019404302A1 (en) 2018-12-19 2021-08-05 The Trustees Of The University Of Pennsylvania Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
KR20210116526A (ko) 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
CN109706121A (zh) * 2019-01-25 2019-05-03 苏州茂行生物科技有限公司 一种基于碱基编辑的通用型car-t细胞及其制备方法和应用
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
AU2020216484A1 (en) 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
US20220098593A1 (en) 2019-02-13 2022-03-31 Beam Therapeutics Inc. Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
EP3924479A4 (en) 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
CN114096666B (zh) 2019-02-13 2025-03-18 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
CN114040970B (zh) 2019-02-13 2024-09-27 比姆医疗股份有限公司 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗
US20220127594A1 (en) 2019-02-13 2022-04-28 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
WO2020176897A1 (en) 2019-02-28 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors and uses thereof
TW202042824A (zh) 2019-03-27 2020-12-01 賓夕法尼亞大學董事會 Tn-MUC1嵌合抗原受體(CAR)T細胞療法
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020227446A1 (en) 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
WO2020227447A1 (en) 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors targeting glypican-2
US20200370013A1 (en) 2019-05-20 2020-11-26 The Trustees Of The University Of Pennsylvania Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
WO2020236982A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Aav delivery of nucleobase editors
JP7679311B2 (ja) 2019-05-21 2025-05-19 ビーム セラピューティクス インク. プログラム可能塩基エディターシステムを用いた一塩基多型編集法
KR20220015382A (ko) 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
AU2020322021A1 (en) 2019-07-30 2022-02-10 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
KR102258713B1 (ko) 2019-07-31 2021-05-31 한양대학교 산학협력단 사이토신 염기교정용 조성물 및 이의 용도
AU2020336969B2 (en) 2019-08-29 2024-12-05 Beam Therapeutics Inc. Compositions and methods for non-toxic conditioning
US20220290121A1 (en) 2019-08-30 2022-09-15 The General Hospital Corporation Combinatorial Adenine and Cytosine DNA Base Editors
AU2020344547A1 (en) 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same
AU2020466994B2 (en) 2019-09-17 2026-05-28 Rutgers, The State University Of New Jersey Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
JP2022552265A (ja) 2019-10-11 2022-12-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 調節可能な細胞局在化のための組換えポリペプチド
US11591607B2 (en) 2019-10-24 2023-02-28 Pairwise Plants Services, Inc. Optimized CRISPR-Cas nucleases and base editors and methods of use thereof
CN114867852A (zh) 2019-10-30 2022-08-05 成对植物服务股份有限公司 V型crispr-cas碱基编辑器及其使用方法
WO2021087356A1 (en) 2019-11-01 2021-05-06 The Trustees Of The University Of Pennsylvania Fibronectin targeting chimeric antigen receptors (cars)
EP4061927A4 (en) 2019-11-20 2024-11-13 Cartherics Pty. Ltd. METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
CN114929250A (zh) 2019-12-18 2022-08-19 爱迪塔斯医药公司 用于疗法的经工程化的细胞
US20210230246A1 (en) 2020-01-15 2021-07-29 The Trustees Of The University Of Pennsylvania Use of inhibitory chimeric receptors to prevent t cell-induced blood brain barrier damage
WO2021158999A1 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Gene editing methods for treating spinal muscular atrophy
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
CN115698285A (zh) 2020-02-14 2023-02-03 小利兰·斯坦福大学董事会 具有cd2激活的嵌合抗原受体
BR112022017732A2 (pt) 2020-03-04 2023-01-17 Suzhou Qi Biodesign Biotechnology Company Ltd Sistema aperfeiçoado de edição de base de citosina
WO2021188840A1 (en) 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
EP4132951A4 (en) 2020-04-09 2025-06-11 Verve Therapeutics, Inc. CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
EP4179079A1 (en) 2020-07-10 2023-05-17 Horizon Discovery Limited Method for producing genetically modified cells
JP7890972B2 (ja) 2020-07-15 2026-07-15 ライフ エディット セラピューティクス,インコーポレイティド ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
EP4211235A2 (en) 2020-09-11 2023-07-19 Lifeedit Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20230383277A1 (en) 2020-10-14 2023-11-30 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
IT202000028688A1 (it) 2020-11-27 2022-05-27 Consiglio Nazionale Ricerche Varianti della citidina deaminasi per l’editazione di basi
EP4274902A4 (en) 2021-01-05 2025-04-16 Revvity Discovery Limited Guide RNA designs and complexes for tracless V-CAS systems
US20240060088A1 (en) 2021-01-05 2024-02-22 Horizon Discovery Limited Guide RNA Designs and Complexes for Type V Cas Systems
CA3207144A1 (en) 2021-01-05 2022-07-14 Horizon Discovery Limited Method for producing genetically modified cells
WO2022150706A2 (en) 2021-01-08 2022-07-14 The General Hospital Corporation Genome editing approaches to treat spinal muscular atrophy
JP2024507533A (ja) 2021-02-19 2024-02-20 ビーム・セラピューティクス・インコーポレイテッド 遺伝子治療のための組み換え狂犬病ウイルス
BR112023019539A2 (pt) 2021-03-26 2023-12-05 Beam Therapeutics Inc Variantes de adenosina desaminase e usos das mesmas
WO2022272292A2 (en) 2021-06-23 2022-12-29 Editas Medicine, Inc. Engineered cells for therapy
WO2023279118A2 (en) 2021-07-02 2023-01-05 University Of Maryland, College Park Cytidine deaminases and methods of genome editing using the same
CA3225808A1 (en) 2021-07-16 2023-01-19 David R. Liu Context-specific adenine base editors and uses thereof
EP4388105A4 (en) 2021-08-16 2026-02-11 Beam Therapeutics Inc Persistent Allogeneic Modified Immune Cells and Their Methods of Use
EP4396207A4 (en) 2021-09-03 2025-07-16 Univ Chicago POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS
GB2702733A (en) 2021-09-22 2026-06-24 Verve Therapeutics Inc Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease
US20230105319A1 (en) 2021-09-24 2023-04-06 Crispr Therapeutics Ag PRODRUG INCORPORATED sgRNA SYNTHESIS
CA3242360A1 (en) 2021-12-10 2023-06-15 Beam Therapeutics Inc. Modified immune cells and methods of using the same
WO2023125814A1 (zh) 2021-12-29 2023-07-06 华东师范大学 腺嘌呤脱氨酶及其应用
WO2023155901A1 (en) 2022-02-17 2023-08-24 Correctsequence Therapeutics Mutant cytidine deaminases with improved editing precision
CN114634923B (zh) 2022-04-07 2024-02-23 尧唐(上海)生物科技有限公司 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途
JP2025517515A (ja) 2022-05-26 2025-06-05 ユーシービー バイオファルマ エスアールエル 新規核酸編集タンパク質
EP4532697A2 (en) 2022-06-03 2025-04-09 Beam Therapeutics Inc. Modified regulatory t cells and methods of using the same
EP4540378A1 (en) 2022-06-20 2025-04-23 CRISPR Therapeutics AG Base editing proteins and uses thereof
JP2025520697A (ja) 2022-06-23 2025-07-03 ビーエーエスエフ アグリカルチュラル ソリューションズ ユーエス エルエルシー 多様化塩基編集
EP4544035A4 (en) 2022-06-27 2026-06-24 Beam Therapeutics Inc ADENOSINE DEAMINASE BASIC EDITORS AND THEIR METHODS OF USE
AU2023325079A1 (en) 2022-08-16 2025-02-13 President And Fellows Of Harvard College Evolved cytosine deaminases and methods of editing dna using same
WO2024063273A1 (en) 2022-09-23 2024-03-28 Institute For Basic Science Novel adenine deaminase variants and a method for base editing using the same
CN120435553A (zh) 2022-09-26 2025-08-05 比姆医疗股份有限公司 合成多肽及其用途
WO2024179426A2 (en) 2023-02-28 2024-09-06 Accuredit Therapeutics (Suzhou) Co., Ltd. Deaminases for use in base editing
WO2024226156A1 (en) 2023-04-27 2024-10-31 University Of Massachusetts Cas-embedded cytidine deaminase ribonucleoprotein complexes having improved base editing specificity and efficiency
KR20260007576A (ko) 2023-04-28 2026-01-14 빔 테라퓨틱스, 인크. 변형된 가이드 rna
CN121889499A (zh) 2023-06-15 2026-04-17 比姆医疗股份有限公司 用于治疗α1-抗胰蛋白酶缺乏症的方法和组合物
CN117965505A (zh) 2023-06-28 2024-05-03 微光基因(苏州)有限公司 工程化的腺苷脱氨酶及碱基编辑器

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075483A (zh) * 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 用于过继细胞治疗的工程改造的细胞
CN109996811A (zh) * 2016-08-03 2019-07-09 约翰·F·迪帕西奥 用于用嵌合抗原受体治疗t细胞恶性肿瘤的car-t细胞的基因编辑
WO2018165631A1 (en) * 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine

Also Published As

Publication number Publication date
CA3155667A1 (en) 2021-04-01
US12594301B2 (en) 2026-04-07
WO2021062227A2 (en) 2021-04-01
US20230021636A1 (en) 2023-01-26
JP2022549916A (ja) 2022-11-29
JP7615134B2 (ja) 2025-01-16
CN120905310A (zh) 2025-11-07
EP4034138A2 (en) 2022-08-03
EP4034138A4 (en) 2024-07-31
CN115279398A (zh) 2022-11-01
AU2020355222A1 (en) 2022-03-24
KR20220090512A (ko) 2022-06-29
WO2021062227A3 (en) 2021-05-06
JP7885317B2 (ja) 2026-07-06
JP2025066723A (ja) 2025-04-23

Similar Documents

Publication Publication Date Title
CN120905310A (zh) 治疗液态癌症的组合物和方法
CN114026227B (zh) 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
CN114630904B (zh) 用于无毒调理的组合物和方法
US20240287453A1 (en) Persistent allogeneic modified immune cells and methods of use thereof
CN120400115A (zh) 脱氨反应脱靶减低的核碱基编辑器和使用其修饰核碱基靶序列的方法
US12576151B2 (en) Fratricide resistant modified immune cells and methods of using the same
WO2021030666A1 (en) Base editing by transglycosylation
CN114072495A (zh) 具有增强的抗肿瘤活性和免疫抑制抗性的经修饰的免疫细胞
US20250090585A1 (en) Modified regulatory t cells and methods of using the same
US20240325533A1 (en) Modified immune cells and methods of using the same
EP4544035A2 (en) Adenosine deaminase base editors and methods for use thereof
CN118234865A (zh) 持久性同种异体修饰免疫细胞及其使用方法
WO2024163603A1 (en) Chimeric pseudotyped recombinant rabies virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant